Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

Published : Nov-2017

No. of Pages : 834

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Glioblastoma Multiforme (GBM) 31
Nov 13, 2017: Theralase Researcher Discovers Super Potent Anti-Cancer Drugs 31
Nov 13, 2017: Oncoceutics to Present Data on Glioblastoma Drug Candidate ONC201 at SNO 31
Nov 09, 2017: Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology 32
Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting 32
Nov 06, 2017: Scientists exploit leaks in blood brain barrier to treat glioblastoma 32
Nov 06, 2017: ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology 33
Oct 17, 2017: Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme 34
Oct 12, 2017: Lenox Hill Hospital participates in clinical research study to test investigational treatment for recurrent brain cancer 34
Oct 11, 2017: Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma 35
Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients 35
Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 36
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 36
Sep 29, 2017: National Cancer Institute Awards Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer 36
Sep 26, 2017: CEO Jeffery Bacha Discusses DelMar's VAL-083 Clinical Trials and the Major Milestones Ahead 37
Sep 25, 2017: Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays 37
Sep 14, 2017: Patrys: PAT-DX1 Active in Pre-clinical Cancer Models 38
Sep 12, 2017: Theralase Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug 38
Sep 11, 2017: DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme 39
Sep 07, 2017: NCCN Announces First Patient Dosed in NCCN-Peregrine Pharmaceuticals Collaborative Study of Bavituximab 40
Sep 06, 2017: DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 40
Sep 01, 2017: DCVax-L Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference 40
Aug 30, 2017: Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company's Innovative Research Approach to Treating Cancer from All Angles 41
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 42
Aug 22, 2017: GDC-0084 Progress Update: On Track for Phase II Commencement in 2017 43
Aug 22, 2017: Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas 43
Clinical Trial Profile Snapshots 45
Appendix 831
Abbreviations 831
Definitions 831
Research Methodology 832
Secondary Research 832
About GlobalData 833
Contact Us 833
Disclaimer 833
Source 834

List of Tables
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2017* 8
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017* 16
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017* 19
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017* 16
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017* 19
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
GlobalData Methodology 832

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027